MegaPro Biomedical Co., Ltd (TPEX:6827)

Market Cap	741.05M -32.2%
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	64.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250,897
Open	11.15
Previous Close	11.45
Day's Range	9.98 - 11.15
52-Week Range	9.47 - 19.60
Beta	0.85
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About MegaPro Biomedical

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6827

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error